Cathie Wood’s ARK sells Twist Bioscience stock, buys Intellia shares

ARK disclosed a net set of biotech portfolio rotations for Tuesday, May 12, 2026, led by the sale of 56,429 shares of Twist Bioscience for $3.17M. It also bought 4,310 shares of Natera for $858K and 40,000 shares of Intellia Therapeutics for $576.8K, while trimming CareDx by 14,403 shares worth $310K. The trades suggest continued repositioning within biotech rather than a broad thematic shift.

Analysis

This flow is less about single-name conviction than a read-through on where incremental biotech capital is being reallocated inside public growth portfolios. TWST and CDNA look like funded exits: that usually matters more for sentiment than fundamentals because these names trade on scarce marginal buyers, so persistent selling can compress multiple faster than earnings revisions would justify. The second-order effect is a relative-liquidity winner set elsewhere in biotech — if ARK is rotating out of lower-quality tools/diagnostics exposure, the freed-up risk budget tends to migrate into names with more binary upside and cleaner catalyst stacks.

NTRA and NTLA being accumulated is notable because both sit closer to platform monetization than point-solution diagnostics. That matters in a weak tape: investors often punish duration and then suddenly reward assets with visible inflection points once macro fear peaks. If the market keeps rotating away from high-multiple hardware-like biotech exposures, these buys can mark the start of a factor trade: long names with embedded optionality and near-term clinical/readout catalysts, short names where valuation is still supported mainly by narrative.

The contrarian read is that ARK’s activity can be procyclical, not predictive; if this is performance-chasing into a biotech bounce, the trades may fade once broader risk appetite improves. The more durable signal is on TWST/CDNA: repeated selling often precedes slower multiple recovery than the rest of the basket, especially when investor attention is pulled to AI/mega-cap and away from healthcare. Over the next 2-6 weeks, watch whether NTRA/NTLA outperform on down-market days; if they do, that confirms real sponsorship rather than one-day inventory management.

Key Decisions for Investors

• Short TWST on any strength over the next 1-3 sessions; use a tight 5-7% stop and look for a 10-15% downside air pocket if redemptions/rotation persist. Best as a tactical fade rather than a core short.
• Pair long NTRA / short TWST for 2-4 weeks: long the name with improving institutional sponsorship and short the one showing persistent distribution. Risk/reward is attractive if the spread widens 8-12% on continued biotech factor rotation.
• Add NTLA as a catalyst-driven long for 1-2 months only if it holds up on a weak tape; the setup is for squeeze potential, not fundamentals. Use call spreads instead of stock to cap gap risk.
• Avoid initiating fresh longs in CDNA until the selling trend stops; if you already own it, sell covered calls into any bounce to monetize decaying sentiment while waiting for flow to turn.